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Objectives: To examine whether the overall results of the CASTLE study pertain to both genders, we analysed the
efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir in 277 female and 606 male patients in the openlabel, multinational trial over 96 weeks. The trial is registered with ClinicalTrials.gov, number NCT00272779.
Methods: Treatment-naive patients aged ≥18 years with HIV-1 RNA ≥5000 copies/mL were randomized to
receive either atazanavir/ritonavir 300/100 mg once daily or lopinavir/ritonavir 400/100 mg twice daily, with
fixed-dose tenofovir/emtricitabine 300/200 mg once daily.
Results: At week 96, confirmed virological response rates (HIV RNA ,50 copies/mL; intent-to-treat analysis) were
higher in women and men receiving atazanavir/ritonavir than those receiving lopinavir/ritonavir and lower in
women than men in both treatment arms (67% of women and 77% of men on atazanavir/ritonavir and 63%
of women and 71% of men on lopinavir/ritonavir). These differences were not observed in the on-treatment
analysis. Mean change in CD4 cell count from baseline to week 96 was 265 cells/mm3 for women and
269 cells/mm3 for men on atazanavir/ritonavir and 298 cells/mm3 for women and 286 cells/mm3 for men on lopinavir/ritonavir. Discontinuation rates were higher in women than men in each treatment arm (22% of women and
15% of men on atazanavir/ritonavir and 29% of women and 18% of men on lopinavir/ritonavir). In women and
men, grade 2–4 nausea and diarrhoea were more frequent in the lopinavir/ritonavir group; jaundice and hyperbilirubinaemia occurred more frequently in the atazanavir/ritonavir group.
Conclusions: Once-daily atazanavir/ritonavir is an effective and well-tolerated therapeutic option for women and
men with HIV-1 infection. The sex-based differences in response may be due to higher discontinuation rates in
women.
Keywords: antiretroviral therapy, protease inhibitors, HIV

Introduction
Of the estimated 35 million people living with HIV, almost half
are women, and this proportion is increasing in several
countries.1,2 Of particular concern are the increases in HIV infection among young women, who now make up .60% of young
adults aged 15– 24 years living with HIV/AIDS.1 Women
account for 25% of new AIDS cases and more than one-third

of new HIV diagnoses in the USA. African–American and Hispanic
women represent a disproportionate percentage of the disease
burden, constituting ,25% of all US women, but accounting
for 79% of new diagnoses.3 Despite the changing epidemiology
of HIV among women, they remain under-represented in most
clinical HIV studies as few women enrol and continue in trials
in the developed world.4,5 Much of the data available on
women with HIV are from studies carried out in resource-limited
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Methods
Study design and participants
Details of the study design and participants were described previously
by Molina et al.17 Briefly, patients were eligible for enrolment if they
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were infected with HIV-1, were aged ≥18 years, were naive to ARV
therapy (,1 week previous ARV experience or ,6 weeks exposure for
prophylaxis or prevention of mother-to-child transmission) and had
HIV-1 RNA ≥5000 copies/mL. Patients were randomized to receive
either atazanavir/ritonavir 300/100 mg once daily or lopinavir/ritonavir
400/100 mg twice daily, each given in combination with fixed-dose tenofovir/emtricitabine 300/200 mg once daily. Patients assigned to lopinavir/
ritonavir were able to switch from the soft-gel capsule to the tablet formulation after 48 weeks. Randomization was in a 1:1 ratio, and was stratified for HIV-1 level (,100000 or ≥100000 copies/mL) and geographical
region.

Research ethics
The study was conducted in accordance with good clinical practice and
the ethical principles of the Declaration of Helsinki. The institutional
review board/independent ethics committee at each study site approved
the protocol, amendments and informed consent before initiation. The
trial is registered with ClinicalTrials.gov, number NCT00272779.

Procedures
Study procedures were outlined in the previous publication17 and continued as described for the duration of the 96 week study. Patients were
assessed at screening, day 1 (baseline) and at weeks 2, 4, 12, 24, 36,
48, 60, 72, 84 and 96, or at early termination. Vital signs and samples
for plasma HIV RNA, CD4 cell count and laboratory tests (serum
chemistry and haematology, fasting lipid profile, urinalysis, hepatitis
co-infection) were taken at all patient visits (except week 2).
The primary endpoint of the CASTLE study was the the proportion of
patients with HIV-1 RNA ,50 copies/mL at week 48, as reported by
Molina et al. 16 In this paper, secondary efficacy endpoints for patients
of female and male gender are reported, including the proportion of
patients with HIV-1 RNA ,50 copies/mL at week 96 and change in absolute CD4 cell count from baseline through week 96. Safety endpoints
assessed at week 96 included frequency of adverse events, serious
adverse events and discontinuation due to adverse events, and
changes from baseline in fasting lipids over time.

Statistical analysis
Statistical methods for the week 96 analysis have been previously published17 and are briefly summarized below. Efficacy results are presented
by the as-randomized treatment regimen [intent-to-treat (ITT)]. Safety
results are presented by the as-treated treatment regimen (i.e. by the
treatment regimen actually received). The gender analysis was not
powered to detect statistical differences, and no statistical comparisons
between treatment arms or between genders were carried out for
this report. The proportion of patients with HIV RNA ,50 copies/mL at
week 96 was assessed with several algorithms and cohorts of randomized patients. The principal analysis was based on the confirmed virological response (CVR) non-completer¼failure (NC ¼F; ITT) definition of
response. Supportive analyses used the virological response-observed
cases (VR-OC) definitions of response and a post hoc cross-sectional
analysis at week 96 in the as-treated population. Observed values were
used to summarize CD4 cell counts and their changes from baseline
through week 96.
Categories of fasting lipid parameters were tabulated through week
96 using observed values. Categories for cholesterol and triglycerides
were defined according to the US National Cholesterol Education
Program (NCEP) Adult Treatment Panel (ATP) III guidelines.18 Analyses
of fasting lipids over time excluded values obtained after patients commenced lipid-lowering agents.
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settings. In addition, as most clinical studies have enrolled fewer
women than men, treatment guidelines are based primarily on
outcomes in men.
Recent studies highlight that despite initial concerns regarding
potential differences in response to antiretroviral (ARV) therapy
across gender, both men and women respond equally well to
therapy. Differences in response typically occur due to a higher
number of discontinuations among women as compared with
men. When efficacy results are censored for discontinuations
other than virological failure, women have responded as well as
men in several clinical trials in both treatment-naive and
treatment-experienced HIV-infected patients.3,6 – 9 The reasons for
the high number of discontinuations among women in HIV clinical
trials are not known. Even though there do not appear to be significant differences in efficacy by sex, gender differences in toxicity and
adverse reactions have been detected, despite the fact that no
major study in treatment-naive patients has been designed or
powered to detect gender differences.5,6,8,10 – 13 As there are
several issues that women must consider when incorporating a
complex ARV regimen into their lives (including contraception, childbearing, breastfeeding and the potential for mother-to-child HIV
transmission), it is imperative to define potential side effects that
may affect the choice of treatment regimen.3,14 HIV stigma and
access to care may also affect outcomes for HIV-infected
women.3,15 For many women, fitting modern regimens and clinic
visits into their busy schedules can be a challenge. Therefore, tailoring ARV treatment regimens to gender may optimize response, tolerability and adherence, and minimize toxicity.
Analyses from the open-label, international CASTLE study
provide much-needed data on the efficacy and tolerability of protease inhibitor (PI)-based regimens in female and male patients.
Findings from a 48 week analysis, reported at the Seventeenth
International AIDS Conference (2008), demonstrated that
treatment-naive women receiving atazanavir/ritonavir or lopinavir/ritonavir (both in combination with tenofovir/emtricitabine)
experienced a greater number of treatment-related adverse
events and slightly lower virological response than males.8
These data are consistent with the gender-based differences previously noted; however, these analyses were not preplanned or
powered to identify differences in efficacy and safety. We
report here results from an analysis assessing the efficacy,
safety and tolerability of atazanavir/ritonavir and lopinavir/ritonavir in combination with tenofovir/emtricitabine in female and
male patients enrolled in the CASTLE study through 96 weeks
of treatment. In the overall CASTLE population, atazanavir/ritonavir was shown to be non-inferior to, with higher virological
response rates than, lopinavir/ritonavir through 96 weeks of
treatment. The difference in response rates in favour of atazanavir/ritonavir at 96 weeks was driven by a higher rate of discontinuation among patients receiving lopinavir/ritonavir. This was
accompanied, in the overall population, by significantly less
lipid elevation and better gastrointestinal tolerability in the atazanavir/ritonavir group than in the lopinavir/ritonavir group.16,17
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Table 1. Baseline characteristics and demographics for female and male patients randomized in CASTLE
ATV/RTV, N ¼440
female, n ¼138

male, n¼302

female, n¼139

33 (20, 56)

Region, n (%)
Africa
Asia
Europe
North America
South America

33 (24)
15 (11)
15 (11)
7 (5)
68 (49)

34 (11)
24 (8)
50 (17)
60 (20)
134 (44)

41 (29)
12 (9)
13 (9)
9 (6)
64 (46)

24 (8)
28 (9)
53 (17)
60 (20)
139 (46)

4 (3)

15 (5)

5 (4)

19 (6)

HIV RNA log10 copies/mL, median (min, max)
HIV RNA ≥100000 copies/mL, n (%)
CD4 cells/mm , median (min, max)

56 (41)
196 (8, 794)

5.06 (3.05, 5.88)
169 (56)
208 (2, 760)

4.87 (3.69, 5.88)
57 (41)
190 (11, 416)

36 (19, 71)

5.00 (3.32, 5.88)
151 (50)
210 (4, 810)

3

CD4 ,50 cells/mm , n (%)

15 (11)

43 (14)

15 (11)

33 (11)

Hepatitis B and/or C co-infection, n (%)

15 (11)

46 (15)

11 (8)

40 (13)

ATV, atazanavir; LPV, lopinavir; RTV, ritonavir.

Results
Disposition and baseline data
Of the 883 HIV-infected, treatment-naive patients randomized
within CASTLE, 277 (31%) were female and 606 (69%) were
male. Few women from developed nations were enrolled in the
CASTLE study; 6% of women were from North America, compared with 48% from South America and 27% from Africa.
Other baseline characteristics for female and male patients
were comparable across the two treatment arms (Table 1).
Thirty-one (22%) women in the atazanavir/ritonavir group
and 40 (29%) women in the lopinavir/ritonavir group discontinued through week 96 (Figure 1). Discontinuation rates were
lower for male patients; 15% and 18% in the atazanavir/ritonavir
and lopinavir/ritonavir groups, respectively. The reasons for discontinuation were similar between the two treatment groups.
However, more women in the lopinavir/ritonavir group than in
the atazanavir/ritonavir group withdrew as a result of suboptimal
adherence (eight versus four) or withdrawn consent (nine versus
three). Other common reasons for discontinuation were adverse
events, lack of efficacy and pregnancy (Figure 1). Adverse events
had only a minor influence on discontinuation rates for both
treatment groups, with six (4%) women in each group, seven
(2%) men in the atazanavir/ritonavir group and 16 (5%) men
in the lopinavir/ritonavir group withdrawing before week 96 for
this reason.

Efficacy
In the CVR analysis (NC¼F; ITT), 67% of women and 77% of men
receiving atazanavir/ritonavir and 63% of women and 71% of men
receiving lopinavir/ritonavir achieved HIV-1 RNA ,50 copies/mL at
96 weeks of treatment (Figure 2). CVR rates were generally lower
in female patients than male patients in both treatment arms.

Virological response rates in the VR-OC analysis were comparable
between treatment groups and between genders (86% of women
and 91% of men on atazanavir/ritonavir and 89% of women and
87% of men on lopinavir/ritonavir achieved HIV-1 RNA ,50 copies/
mL) at 96 weeks of treatment (Figure 2). Response rates (HIV RNA
,50 copies/mL) by cross-sectional analysis at 96 weeks in the
as-treated population were 69% (95/138) of female patients
and 77% (234/303) of male patients for atazanavir/ritonavir and
63% (88/139) of female patients and 70% (210/298) of male
patients for lopinavir/ritonavir.
The mean change in CD4 cell count from baseline to week 96
was similar between the two treatment groups, at 265 cells/mm3
in female patients and 269 cells/mm3 in male patients on
atazanavir/ritonavir and 298 cells/mm3 in female patients and
286 cells/mm3 in male patients on lopinavir/ritonavir.

Safety
Eight hundred and seventy-eight subjects received study drug
and were included in safety analyses. Three subjects were randomized to lopinavir/ritonavir but received atazanavir/ritonavir
during the entire treatment period. No unexpected adverse
events occurred, and adverse events were not treatment limiting
in most cases. Two (1%) deaths occurred among women in the
study, both in the lopinavir/ritonavir group. Four men (1%) in the
lopinavir/ritonavir group and six men (2%) in the atazanavir/
ritonavir treatment group died during the study. None of the
deaths were considered to be related to the study drugs.
Serious adverse events were reported by 20 (14%) women and
43 (14%) men in the atazanavir/ritonavir group and 17 (12%)
women and 33 (11%) men in the lopinavir/ritonavir group. All
but a few serious adverse events were reported by ,1% of the
population. There were no reports of myocardial infarction in
either treatment group.
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4.87 (2.60, 5.88)

37 (19, 63)

male, n¼304

Age, median years (min, max)

CDC class C AIDS, n (%)

35 (19, 72)

LPV/RTV, N¼443

Squires et al.

883 patients randomized

443 patients allocated to lopinavir/ritonavir

440 patients allocated to atazanavir/ritonavir

138 women

302 men

139 women

304 men

138

Treated

300

139

Treated

301

31 (22%)

Discontinuations

45 (15%)

40 (29%)

Discontinuations

55 (18%)

8 (6%)
6

Lack of

(4%)b

efficacya

Adverse event

8 (3%)

6 (4%)

(2%)c

(4%)d

7

6

Lack of

efficacya

4 (1%)

Adverse event

16 (5%)e

Pregnancyf

0

7 (5%)

Pregnancyf

0

4 (3%)

Poor/noncompliance

8 (3%)

8 (6%)

Poor/noncompliance

8 (3%)

3 (2%)

Withdrew
consent

2 (<1%)

9 (6%)

Withdrew
consent

9 (3%)

2 (1%)

Lost to follow-up

8 (3%)

1 (<1%)

Lost to follow-up

12 (4%)

1 (<1%)

No longer meets
study criteria

3 (<1%)

0

No longer meets
study criteria

3 (<1%)

0

Death

6 (2%)

2 (1%)

Death

3 (<1%)

0

Other

1 (<1%)

1 (<1%)

Other

0

0

Discontinued at
week 96

0

2

(1%)g

Discontinued at
week 96

2

(<1%)h

Patients with HIV RNA <50 copies/mL (%)

Figure 1. Trial profile for female and male patients in the CASTLE study. aInsufficient viral load response determined by investigators. bTwo cases of
rash, one case of tuberculosis (TB), one case of thrombocytopenia, one gastrointestinal problem and one gastrointestinal problem plus dizziness,
jaundice, hepatomegaly and hyperbilirubinaemia. cTwo cases of jaundice, two gastrointestinal problems, one case of abdominal pain, one case of
Mycobacterium infection and one case of Fanconi syndrome. dTwo cases of TB, one case of hypersensitivity, one case of hypertrophic
cardiomyopathy, one case of rash and one case of proteinuria. eSeven cases of diarrhoea, one case of furnicle, one case of major depression, one
case of rash, one case of rhabdomycosis, one case of lipoma, two cases of hyperlipidaemia, one case of lipodystrophy and one case of Kaposi’s
sarcoma. fProtocol-defined for discontinuation. gOne pregnancy and one poor/non-compliance. hOne lost to follow-up and one poor/non-compliance.

100
90
80
70

ATV/RTV female
ATV/RTV male
77
67

LPV/RTV female
LPV/RTV male

86

91

89

87

71
63

60
50
40
30
20
10
0

n = 93 n = 234 n = 87 n = 215
CVR, NC = F

n = 94 n = 232 n = 88 n = 214
VR-OC

Figure 2. CVR (HIV RNA ,50 copies/mL) at week 96 in the ITT (NC¼F) and VR-OC (on-treatment) analyses. Response rates (HIV RNA ,50 copies/mL)
by cross-sectional analysis at 96 weeks in the as-treated population were: atazanavir/ritonavir (ATV/RTV), 69% of female patients and 77% of male
patients; and lopinavir/ritonavir (LPV/RTV), 63% of female patients and 70% of male patients.
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Table 2. Selected grade 2 –4 treatment-related adverse events in female and male patients in each treatment group through week 96
ATV/RTV
Adverse events, n (%)

LPV/RTV

female, n ¼138

male, n¼303

female, n ¼139

male, n¼298

45 (33)
10 (7)
4 (3)
15 (11)
6 (4)
7 (5)
2 (1)

88 (29)
8 (3)
7 (2)
29 (10)
15 (5)
7 (2)
3 (,1)

46 (33)
19 (14)
13 (9)
1 (,1)
0
4 (3)
3 (2)

94 (32)
14 (5)
41 (14)
1 (,1)
0
6 (2)
4 (1)

Any adverse event
Nausea
Diarrhoea
Hyperbilirubinaemiaa
Jaundice/scleral icterus
Rashb
Vomiting

Increase from baseline at week 96 (%)

70

ATV/RTV female
ATV/RTV male

60

LPV/RTV female
LPV/RTV male

58

50
40

40

34

30

25 25

20
10
0

17 17 17

16
7

8

Total
cholesterol

LDL
cholesterol

19

22

25

21

24
18

14

HDL
cholesterol

3

4

Non-HDL
cholesterol

Triglycerides

Figure 3. Mean percentage change in fasting lipid concentrations in female and male patients from baseline through week 96 (as-treated). ATV,
atazanavir; LPV, lopinavir; RTV, ritonavir.

The proportion of women experiencing any grade 2 –4
treatment-related adverse event was identical in both treatment
groups, at 33% (Table 2). Twenty-nine percent of men in the atazanavir/ritonavir arm and 32% of men in the lopinavir/ritonavirtreatment arm experienced grade 2– 4 treatment-related
adverse events. Grade 2 –4 treatment-related nausea and
diarrhoea were more common among women and men in the
lopinavir/ritonavir group than in the atazanavir/ritonavir group;
however, jaundice/scleral icterus and hyperbilirubinaemia
occurred more frequently in women and men receiving atazanavir/ritonavir than in those receiving lopinavir/ritonavir. Grade 2 –4
treatment-related rash occurred in 5% and 3% of women and
2% and 2% of men receiving atazanavir/ritonavir and lopinavir/
ritonavir, respectively.
Figure 3 shows that the mean percentage changes in fasting
lipid concentrations over 96 weeks were generally greater in
women and men receiving lopinavir/ritonavir than in those
receiving atazanavir/ritonavir. In the atazanavir/ritonavir arm,
mean changes from baseline in all lipid parameters were lower
in women than in men. In the lopinavir/ritonavir arm, mean

changes from baseline were lower in women than in men for
non-high-density lipoprotein (non-HDL) cholesterol and triglycerides, higher for women than men for HDL cholesterol and similar
in women and men for total cholesterol and low-density lipoprotein (LDL) cholesterol. More women and men receiving
lopinavir/ritonavir (9%) than atazanavir/ritonavir (2%) initiated
lipid-lowering therapy after the start of study therapy. Women
and men in both treatment groups had optimal median fasting
total cholesterol, HDL cholesterol, non-HDL cholesterol and LDL
cholesterol concentrations at week 96 as defined by the NCEP
ATP III guidelines. Men receiving lopinavir/ritonavir had median
fasting triglyceride concentrations (177 mg/dL) above the NCEP
ATP III guidelines at 96 weeks.

Discussion
The findings of this analysis of response to therapy across male
and female genders were consistent with the overall results for
the CASTLE study.17 In the ITT analysis, women and men
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ATV, atazanavir; LPV, lopinavir; RTV, ritonavir.
a
Hyperbilirubinaemia also includes blood bilirubin abnormal, blood bilirubin increased, blood bilirubin unconjugated and blood bilirubin unconjugated
increased from the INVESTIGATIONS system organ class.
b
Rash includes dermatitis allergic, prurigo, psoriasis, rash, rash erythematous, rash generalized, rash maculopapular, rash papular, rosacea and
urticaria.
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of women in clinical trials is increasing, their numbers remain
low at only 20% in the AIDS Clinical Trials Group (ACTG5142)
study,30 22% in the KLEAN study,21 30% in the ARTEMIS
study22 and 31% in the CASTLE study.16
There are several factors exclusive to women that may influence the decision to enrol in, or continue to participate in, a clinical study. Women of childbearing potential need to consider
what contraception they would use when participating in clinical
studies as few ARV drugs are indicated for concomitant use with
contraceptive drugs.3,31 – 33 Several PIs may increase or decrease
the levels of contraceptives and may result in adverse events.14
The potential teratogenic risk if pregnancy should occur may also
deter women from enrolling or continuing in clinical studies.
Nonetheless, for HIV-infected women who want to become
pregnant, ARV therapy can reduce the risk of mother-to-child
HIV transmission.3,14 HIV-infected women are also more likely
to have financial problems or experience discrimination than
HIV-infected men and this may influence a woman’s willingness
to participate in a clinical study.34 However, most of these data
are obtained from studies carried out in the developing world.
Until more women from the developed world participate in clinical studies, the reasons for fewer enrolments and more discontinuations among women than among men will not be fully
understood.
Limitations of the study include its open-label design, and the
fact that it was not specifically designed or powered to investigate the influence of gender on outcomes. A larger number of
female patients would enable more meaningful comparisons
between the two treatment groups.
In summary, the results of this study show that atazanavir/
ritonavir is an effective once-daily boosted PI regimen that in
combination with other ARVs is well tolerated and appropriate
for use in HIV-infected women and men. The lower response
rates observed in women than in men may have been due to
higher discontinuation rates in women in both treatment arms,
suggesting the need for additional research to understand the
reasons why women are less likely to complete clinical trials.
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receiving atazanavir/ritonavir had higher virological response
rates than those receiving lopinavir/ritonavir, and women in
either treatment arm had lower virological response rates than
men. Through 96 weeks of treatment, gastrointestinal tolerability
was better and there was less elevation of lipids among women
and men receiving atazanavir/ritonavir than those receiving lopinavir/ritonavir, which is similar to the trend observed in the
overall population.17 It is possible that increased gastrointestinal
toxicity contributed to the higher rate of treatment discontinuation in the lopinavir/ritonavir group; however, this requires
further investigation.
The virological responses observed in the 96 week CASTLE
study are comparable to those reported for other studies of atazanavir/ritonavir19,20 and lopinavir/ritonavir21,22 after taking into
account the different study designs and subjects. The findings
are also consistent with those reported for studies of other
PIs.6,21 – 24 Findings from our CVR analysis suggest that the efficacy of atazanavir/ritonavir and lopinavir/ritonavir may be
lower in women than in men. However, these differences were
not observed in the VR-OC on-treatment analysis, which
showed that all observed virological response rates were comparable between treatment groups and between genders after
96 weeks of treatment. These findings are consistent with the
overall results for the CASTLE study in which the difference in
response between treatment arms in the ITT analysis at
96 weeks was driven by a similar virological response rate with
a higher rate of discontinuation among patients receiving
lopinavir/ritonavir.17 In this analysis, the difference in virological
response observed between genders in the ITT analysis at
96 weeks may have been due to the higher rate of discontinuation among women than among men in each treatment arm.
Similar differences in response to once- or twice-daily lopinavir/
ritonavir and tenofovir/emtricitabine between men and women
have been reported,25 while other studies have found no genderrelated differences in response rates to fosamprenavir/ritonavir26
and darunavir/ritonavir6,27 in treatment-naive patients or combination ARV regimens in general.28
In our study, a greater proportion of women than men discontinued the study before week 96 in both treatment groups,
a trend that has also been observed in previous studies.5 – 9
This difference in the rate of discontinuation was partly driven
by pregnancy (4% –5%) among women in both treatment
groups. In addition, more women (6%) than men (3%) discontinued due to suboptimal adherence in the lopinavir/ritonavir arm.
Whether the difference in compliance between women in the
two treatment arms and between women and men is related
to the higher rate of gastrointestinal side effects with lopinavir/
ritonavir is unknown. There are several factors that may influence women’s compliance with HIV regimens, including busy
daily schedules, childcare responsibilities, social relationships,
emotional well-being and therapy-induced changes in body
appearance, such as weight gain.29
It is not known why women discontinue clinical trials more
frequently than men. The Gender, Race and Clinical Experience
(GRACE) study, which assessed darunavir/ritonavir (plus
investigator-selected background regimens) in 287 and 142
treatment-experienced HIV-infected men and women, respectively, found a similar trend. At 48 weeks there was a higherthan-expected rate of discontinuation due to loss of follow-up,
relocation and withdrawal of consent.5 Although the numbers

Comparative gender analysis: CASTLE study

Tobira. M. J. has received honoraria from Bristol-Myers Squibb, GlaxoSmithKline, Tibotec, ViiV Healthcare, Abbott and MSD. R. Y., J. U.,
L. S. and D. M. are employees of and stockholders in Bristol-Myers
Squibb. J. A. was employed by Bristol-Myers Squibb at the time the
research was conducted.
C. Jenkins and J. Turner, of PAREXEL, provided assistance in preparing
and editing the manuscript.

Author contributions
D. M. and R. Y. provided scientific input into the study design and study
protocol. R. Y. did all the statistical analyses. All authors assessed clinical
data from the study and contributed to the drafting and editing of the
manuscript.

References

2 UNAIDS/WHO. AIDS Epidemic Update, 2009. http://data.unaids.org/
pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (24 April 2010, date
last accessed).
3 Belden KA, Squires KE. HIV infection in women: do sex and gender
matter? Curr Infect Dis Rep 2008; 10: 423–31.
4 Pardo M, Ruiz M, Gimeno A. Gender bias in clinical trials of AIDS drugs.
In: Abstracts of the Fourteenth International AIDS Conference, Barcelona,
Spain, 2002. Abstract WePeB5964. http://gateway.nlm.nih.gov/gw/Cmd?
GMResultsSummary%261oc=nccs (25 October 2010, date last accessed).
5 Currier J, Averitt BD, Hagins D et al. Sex-based outcomes of darunavirritonavir therapy: a single-group trial. Ann Intern Med 2010; 153: 349–57.

efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV
Med 2006; 7: 85 –98.
13 Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent
toxicity-driven switches of highly active antiretroviral therapy. The
ATHENA cohort. AIDS 2002; 16: 737– 45.
14 Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected
Adults and Adolescents, December 1, 2009. http://www.aidsinfo.nih.
gov/ContentFiles/AdultandAdolescentGL.pdf (10 December 2009, date
last accessed).
15 Jacobs RJ, Kane MN. HIV-related stigma in midlife and older women.
Soc Work Health Care 2010; 49: 68–89.
16 Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily
atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in
combination with tenofovir and emtricitabine, for management of
antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety
results of the CASTLE study. Lancet 2008; 372: 646– 55.
17 Molina JM, Andrade-Villaneuva J, Echevarria J et al. Once-daily
atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in
combination with tenofovir and emtricitabine, for management of
antiretroviral-naive HIV-1-infected patients: 96-week efficacy and
safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:
323–32.
18 Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation
2002; 106: 3143– 421.
19 Malan DR, Krantz E, David N et al. Efficacy and safety of atazanavir,
with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir
Immune Defic Syndr 2008; 47: 161– 7.

6 Fourie J, Flamm J, Rodriguez-French A. ARTEMIS: week 96 safety and
efficacy of darunavir/r by gender, age and race. In: Abstracts of the
Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention,
Cape Town, South Africa, 2009. Abstract CDB072. http://library.iasociety.
org/AbstractView.aspx?confID=2009&abstractId=1831
(25
October
2010, date last accessed).

20 Elion R, Cohen C, Ward D et al. Evaluation of efficacy, safety,
pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive
patients treated with ritonavir-boosted atazanavir plus fixed-dose
tenofovir DF/emtricitabine given once daily. HIV Clin Trials 2008; 9:
213–24.

7 Walmsley SL, Squires K, Weiss L et al. Multidrug-experienced HIV-1infected women demonstrated similar virological and immunological
responses to tipranavir/ritonavir compared with men. AIDS 2009; 23:
429–31.

21 Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a
randomised non-inferiority trial. Lancet 2006; 368: 476–82.

8 Absalon J, Uy J, Yang R et al. Gender-based differences in ARV-naive
patients treated with boosted protease inhibitors: results from the
CASTLE study (AI424138). In: Abstracts of the Seventeenth International
AIDS Conference, Mexico City, 2008. Abstract TUPE0062. http://www.
aids2008-abstracts.org/aids2008_book_vol1_web.pdf (25 October 2010,
date last accessed).

22 Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily
darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive
HIV-1-infected patients at week 48. AIDS 2008; 22: 1389 –97.

9 Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical
response to highly active antiretroviral therapy: the gender issue revisited.
J Acquir Immune Defic Syndr 2003; 32: 452–61.

24 Gathe J, da Silva B, Loutfy M. Study M05-730 primary efficacy results
at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir
tablets once daily vs twice daily, co-administered with tenofovir and
emtricitabine in ARV-naive HIV-1-infected subjects. In: Abstracts of the
Fifteenth Conference on Retrovirus and Opportunistic Infections, Boston,
MA, 2008. Abstract 775. http://www.retroconference.org/2008/PDFs/775.
pdf (25 October 2010, date last accessed).

10 Murphy RL, Gulick RM, DeGruttola V et al. Treatment with amprenavir
alone or amprenavir with zidovudine and lamivudine in adults with
human immunodeficiency virus infection. AIDS Clinical Trials Group 347
Study Team. J Infect Dis 1999; 179: 808–16.
11 Tedaldi EM, Absalon J, Thomas AJ et al. Ethnicity, race, and gender.
Differences in serious adverse events among participants in an
antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir
Immune Defic Syndr 2008; 47: 441–8.
12 Kumar PN, Rodriguez-French A, Thompson MA et al. A prospective,
96-week study of the impact of Trizivir, Combivir/nelfinavir, and
lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and

23 Ananworanich J, Gayet-Ageron A, Ruxrungtham K et al. Long-term
efficacy and safety of first-line therapy with once-daily saquinavir/
ritonavir. Antivir Ther 2008; 13: 375– 80.

25 da Silva BA, Cohen D, Gibbs S et al. Impact of gender on response to
lopinavir/ritonavir (LPV/r) tablets dosed QD or BID administered with
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in
antiretroviral-naı̈ve (ARV) subjects: results from study M05-730. In:
Abstracts of the Seventeenth International AIDS Conference, Mexico City,
2008. Abstract TUPE0069. http://www.aids2008-abstracts.org/aids2008_
book_vol1_web.pdf (25 October 2010, date last accessed).

369

Downloaded from jac.oxfordjournals.org at Thomas Jefferson University, Scott Library on June 27, 2011

1 UNAIDS. 2008 Report on the Global HIV/AIDS Epidemic. http://www.
unaids.org/en/knowledgecentre/hivdata/globalreport/2008/2008_global_
report.asp (24 April 2010, date last accessed).

JAC

Squires et al.

26 Hoffman RM, Umeh OC, Garris C et al. Evaluation of sex differences of
fosamprenavir (with and without ritonavir) in HIV-infected men and
women. HIV Clin Trials 2007; 8: 371– 80.

30 Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens
for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:
2095– 106.

27 Andrade-Villaneuva J, Herrera G, Chiliade P et al. ARTEMIS: week 48
safety and efficacy of darunavir/r by gender, age and race. In: Abstracts
of the Seventeenth International AIDS Conference, Mexico City, 2008.
Abstract TUPE0064. http://www.aids2008-abstracts.org/aids2008_book_
vol1_web.pdf (25 October 2010, date last accessed).

31 Kaletra. [US prescribing information]. Chicago, IL: Abbott Laboratories;
2009.

28 Mocroft A, Gill MJ, Davidson W et al. Are there gender differences in
starting protease inhibitors, HAART, and disease progression despite
equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475–82.
29 Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in
HIV-infected women. AIDS Care 2000; 12: 377–86.

32 Reyataz. [US prescribing information]. Princeton, NJ: Bristol-Myers
Squibb; 2009.
33 Zhang J, Chung E, Yones C et al. The effect of atazanavir/ritonavir on
the pharmacokinetics of an oral contraceptive containing ethinyl
estradiol and norgestimate in healthy women. Antivir Ther in press.
34 Gordillo V, Fekete EM, Platteau T et al. Emotional support and gender
in people living with HIV: effects on psychological well-being. J Behav Med
2009; 32: 523–31.

Downloaded from jac.oxfordjournals.org at Thomas Jefferson University, Scott Library on June 27, 2011

370

